NRF2 activation promotes aggressive lung cancer and associates with poor clinical outcomes.

CONCLUSIONS: Our in vivo modeling establishes NRF2 activation as a critical oncogenic driver, cooperating with STK11 loss and KRAS activation to promote aggressive LUAD. In patients, oncogenic events alter the tumor immune contexture, possibly impacting treatment responses. Importantly, patients with NRF2 activated non-squamous or squamous tumors have poor prognosis and show limited response to anti-PD-L1 treatment.
PMID: 33077574 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 19, 2020 Category: Cancer & Oncology Authors: Singh A, Daemen A, Nickles D, Jeon SM, Foreman O, Sudini K, Gnad F, Lajoie S, Gour N, Mitzner W, Chatterjee S, Choi EJ, Ravishankar B, Rappaport A, Patil NS, McCleland M, Johnson L, Acquaah-Mensah GK, Gabrielson E, Biswal S, Hatzivassiliou G Tags: Clin Cancer Res Source Type: research